Cullinan Therapeutics’ (CGEM) “Buy” Rating Reiterated at HC Wainwright

Cullinan Therapeutics (NASDAQ:CGEM)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $35.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 133.96% from the stock’s current price. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q1 2027 earnings at ($0.95) EPS, Q2 2027 earnings at ($0.96) EPS, Q3 2027 earnings at ($0.98) EPS, Q4 2027 earnings at ($1.00) EPS and FY2027 earnings at ($3.89) EPS.

Other equities research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 13th. Wedbush raised their price objective on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. BTIG Research restated a “buy” rating and set a $40.00 price objective on shares of Cullinan Therapeutics in a report on Friday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. Finally, TD Cowen upgraded shares of Cullinan Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.71.

Cullinan Therapeutics Price Performance

CGEM traded up $0.43 during mid-day trading on Friday, hitting $14.96. The stock had a trading volume of 312,894 shares, compared to its average volume of 901,550. The stock’s fifty day simple moving average is $19.56 and its 200-day simple moving average is $16.73. The firm has a market capitalization of $962.83 million, a price-to-earnings ratio of -4.83 and a beta of -0.04. Cullinan Therapeutics has a 1-year low of $5.68 and a 1-year high of $23.19.

Cullinan Therapeutics (NASDAQ:CGEM) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01). As a group, research analysts expect that Cullinan Therapeutics will post -3.08 earnings per share for the current fiscal year.

Insider Transactions at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $21.57, for a total value of $172,560.00. Following the sale, the insider directly owned 158,844 shares in the company, valued at approximately $3,426,265.08. The trade was a 4.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have sold 46,000 shares of company stock valued at $922,920. 8.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cullinan Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in Cullinan Therapeutics in the 2nd quarter valued at $95,289,000. Blue Owl Capital Holdings LP acquired a new stake in Cullinan Therapeutics in the 2nd quarter valued at $28,039,000. Dimensional Fund Advisors LP increased its stake in Cullinan Therapeutics by 6.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company’s stock valued at $12,870,000 after buying an additional 57,259 shares during the last quarter. Boone Capital Management LLC acquired a new stake in Cullinan Therapeutics in the 2nd quarter valued at $12,828,000. Finally, Boothbay Fund Management LLC acquired a new stake in Cullinan Therapeutics in the 4th quarter valued at $12,803,000. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs.

Cullinan’s pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses.